Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Baxter
Fish and Richardson
Colorcon
Cantor Fitzgerald
Federal Trade Commission
Cerilliant
Johnson and Johnson
Chubb
Chinese Patent Office

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,162,915

« Back to Dashboard

Which drugs does patent 8,162,915 protect, and when does it expire?


Patent 8,162,915 protects NAROPIN and is included in one NDA. There have been three Paragraph IV challenges on Naropin.

This patent has twenty-two patent family members in nineteen countries.

Summary for Patent: 8,162,915

Title:Connector for packings containing medical liquids, and corresponding packing for medical liquids
Abstract: A connector for packings containing medical liquids, particularly infusion, transfusion or enteral bags, comprises a connecting part (1) for accommodating a spike for drawing out the liquid and comprises a closure part (3) that closes the passage (2) inside the connecting part (1). The connecting part (1) has an elastically deformable pinching off part (4) provided in the form of a tubular section with a non-circular cross-section. A base part (5), which widens on both sides is adjoined to said pinching off part (4) and can be integrated in the packing. During manufacturing, the packing is filled with liquid via the connecting part. After filling, the pinching off part is pressed together whereby preventing liquid from escaping. Afterwards, the closure part is placed onto the connecting part. The manufacturing of the packing is simplified by virtue of the fact that an additional tube for connecting the connector and packing is rendered unnecessary.
Inventor(s): Brandenburger; Torsten (Niddatal, DE), Heilmann; Klaus (St. Wendel, DE), Knierbein; Bernd (Neu-Anspach, DE)
Assignee: Fresenius Kabi Deutschland GmbH (Bad Homburg, DE)
Application Number:10/550,477
Patent Claim Types:
see list of patent claims
Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Fresenius Kabi UsaNAROPINropivacaine hydrochlorideSOLUTION;INJECTION020533-006Sep 24, 1996APRXYesNo► Subscribe► Subscribe► SubscribeY
Fresenius Kabi UsaNAROPINropivacaine hydrochlorideSOLUTION;INJECTION020533-007Sep 24, 1996RXYesNo► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,162,915

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany103 13 760Mar 27, 2003
PCT Information
PCT FiledJanuary 22, 2004PCT Application Number:PCT/EP2004/000487
PCT Publication Date:October 07, 2004PCT Publication Number: WO2004/084793

International Patent Family for Patent: 8,162,915

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1605891► Subscribe
Poland209530► Subscribe
Poland377727► Subscribe
Norway331003► Subscribe
MexicoPA05010292► Subscribe
Norway20053981► Subscribe
South Korea100918859► Subscribe
South Korea20050111756► Subscribe
Japan4533887► Subscribe
Japan2006521124► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Federal Trade Commission
Cipla
Express Scripts
Johnson and Johnson
Queensland Health
Dow
Cerilliant
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot